http://www.cnr.it/ontology/cnr/individuo/prodotto/ID167951

Adjuvant therapy of melanoma patients (stage II, III): a pilot immuno-toxicological study (Articolo in rivista)

Type

Label

Adjuvant therapy of melanoma patients (stage II, III): a pilot immuno-toxicological study (Articolo in rivista) (literal)

Anno

Alternative label

Tricarico M.1; Nunziata C.2; Atzori F.3; Concolino F.3; Macchini V.3; D'Atri S.3; Prete S.P.4; Turriziani M.5; Lanzilli G.1; Sera F.6; Abeni D.3; Albanesi V.3; Bonmassar E.3; Pagani E.3 (2004)
Adjuvant therapy of melanoma patients (stage II, III): a pilot immuno-toxicological study
in Journal of experimental & clinical cancer research (Testo stamp.)
(literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

Tricarico M.1; Nunziata C.2; Atzori F.3; Concolino F.3; Macchini V.3; D'Atri S.3; Prete S.P.4; Turriziani M.5; Lanzilli G.1; Sera F.6; Abeni D.3; Albanesi V.3; Bonmassar E.3; Pagani E.3 (literal)

Pagina inizio

Pagina fine

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume

Rivista

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroFascicolo

Note

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni

1 Inst. of Neurobiology and Molecular Medicine, CNR, Rome, Italy; 2 San Giuseppe Hospiutal, ASL RM-H, Albano; 3 Ist. Dermopatico dell'Immacolata (IDI-IRCCS), Rome; 4 Dept. of Neurosciences, Tor Vergata University, Rome; 5 Dept. of Internal Medicine, Tor Vergata University, Rome; 6 Molecular and Nutritional Epidemiology Unit, CSPO, Scientific Institute of Tuscany, Florence, Italy (literal)

Titolo

Adjuvant therapy of melanoma patients (stage II, III): a pilot immuno-toxicological study (literal)

Abstract

A pilot study was conducted to assess the tolerability and the effect on host immunity of a post-surgery adjuvant treatment of melanoma patients with an anti-angiogenic agent, Tamoxifen (TAM, 20 mg/die p.o., daily), combined with immunomodulating cytokines, i.e. recombinant interleukin-2 (IL-2, 4 MUI/m2 s.c., day 8,10,12) and alpha-2b-interferon (IFN, 3 MUI/m2 i.m., day 15,17,19), starting a new cycle on day 21, for a total of 12 cycles. Fifty patients (pts) entered into the study, 27 males and 23 females with a median age of 55 years (range 25-75), performance status (ECOG) 0 with melanoma stage IIA (12 patients), stage IIB (28 patients), stage III (10 patients). Preliminary in vitro studies showed that TAM does not interfere with up-regulation of natural immunity induced by IFN, IL-2, or IFN + IL-2 in normal peripheral blood mononuclear cells (MNC). The clinical study indicates that the protocol was well tolerated. Increase of NK and LAK activity of patient MNC was observed on day 15. The mean disease-free interval was 10 months and 40 pts were alive at 5 years of follow-up. Further investigations should be performed to test effectiveness of this protocol in a randomized study. (literal)

Prodotto di